Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Duvelisib in Early-stage Mycosis Fungoides
NCT07714187Phase 1Not yet recruiting
- Sponsor
- Secura Bio
- Start
- Jan 2027
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of duvelisib in mycosis fungoides (MF), sponsored by Secura Bio. Primary endpoints: Number of Participants with Treatment-emergent Adverse Events at Day 114, Local Skin Reactions to Duvelisib Topical Gel at Day 114 and 2 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
duvelisib
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT07714187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714187.